GFAP and Alzheimer disease: Yet not only GFAP, as an inflammatory marker of astrocytes, but also other biomarkers of immune cells of the brain (microglia and astrocytes) and blood (T cells and monocytes) show changes in AD individuals and likely play a major role in AD physiopathology and could serve as potential future biomarkers (see Figure 1), as discussed in the sections above.